Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Identifieur interne : 003D64 ( Main/Exploration ); précédent : 003D63; suivant : 003D65Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.
Auteurs : Aeron C. Hurt [Australie] ; Pina Iannello ; Kim Jachno ; Naomi Komadina ; Alan W. Hampson ; Ian G. Barr ; Jennifer L. Mckimm-BreschkinSource :
- Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2006.
Descripteurs français
- KwdFr :
- Acides sialiques (pharmacologie), Acétamides (pharmacologie), Antienzymes (pharmacologie), Antienzymes (usage thérapeutique), Antiviraux (pharmacologie), Baculoviridae (génétique), Concentration inhibitrice 50 (MeSH), Cyclopentanes (pharmacologie), Données de séquences moléculaires (MeSH), Femelle (MeSH), Grippe humaine (traitement médicamenteux), Grippe humaine (virologie), Guanidines (pharmacologie), Humains (MeSH), Nourrisson (MeSH), Oséltamivir (MeSH), Protéines recombinantes (antagonistes et inhibiteurs), Pyrannes (pharmacologie), Résistance virale aux médicaments (génétique), Sialidase (antagonistes et inhibiteurs), Sialidase (génétique), Substitution d'acide aminé (MeSH), Séquence nucléotidique (MeSH), Tests de sensibilité microbienne (MeSH), Virus influenza B (effets des médicaments et des substances chimiques), Virus influenza B (isolement et purification), Zanamivir (MeSH).
- MESH :
- antagonistes et inhibiteurs : Protéines recombinantes, Sialidase.
- effets des médicaments et des substances chimiques : Virus influenza B.
- génétique : Baculoviridae, Résistance virale aux médicaments, Sialidase.
- isolement et purification : Virus influenza B.
- pharmacologie : Acides sialiques, Acétamides, Antienzymes, Antiviraux, Cyclopentanes, Guanidines, Pyrannes.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antienzymes.
- virologie : Grippe humaine.
- Concentration inhibitrice 50, Données de séquences moléculaires, Femelle, Humains, Nourrisson, Oséltamivir, Substitution d'acide aminé, Séquence nucléotidique, Tests de sensibilité microbienne, Zanamivir.
English descriptors
- KwdEn :
- Acetamides (pharmacology), Amino Acid Substitution (MeSH), Antiviral Agents (pharmacology), Baculoviridae (genetics), Base Sequence (MeSH), Cyclopentanes (pharmacology), Drug Resistance, Viral (genetics), Enzyme Inhibitors (pharmacology), Enzyme Inhibitors (therapeutic use), Female (MeSH), Guanidines (pharmacology), Humans (MeSH), Infant (MeSH), Influenza B virus (drug effects), Influenza B virus (isolation & purification), Influenza, Human (drug therapy), Influenza, Human (virology), Inhibitory Concentration 50 (MeSH), Microbial Sensitivity Tests (MeSH), Molecular Sequence Data (MeSH), Neuraminidase (antagonists & inhibitors), Neuraminidase (genetics), Oseltamivir (MeSH), Pyrans (pharmacology), Recombinant Proteins (antagonists & inhibitors), Sialic Acids (pharmacology), Zanamivir (MeSH).
- MESH :
- chemical , antagonists & inhibitors : Neuraminidase, Recombinant Proteins.
- chemical , genetics : Neuraminidase.
- chemical , pharmacology : Acetamides, Antiviral Agents, Cyclopentanes, Enzyme Inhibitors, Guanidines, Pyrans, Sialic Acids.
- drug effects : Influenza B virus.
- drug therapy : Influenza, Human.
- genetics : Baculoviridae, Drug Resistance, Viral.
- isolation & purification : Influenza B virus.
- chemical , therapeutic use : Enzyme Inhibitors.
- virology : Influenza, Human.
- Amino Acid Substitution, Base Sequence, Female, Humans, Infant, Inhibitory Concentration 50, Microbial Sensitivity Tests, Molecular Sequence Data, Oseltamivir, Zanamivir.
Abstract
An influenza B virus from an infant with no history of treatment or contact with neuraminidase inhibitors demonstrated a significant reduction in sensitivity to these drugs. Here, we describe the analysis of a mixed viral population that contained a novel D197E amino acid substitution that was responsible for this reduction.
DOI: 10.1128/AAC.50.5.1872-1874.2006
PubMed: 16641465
PubMed Central: PMC1472236
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.</title>
<author><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Rd., Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Rd., Parkville, Victoria 3052</wicri:regionArea>
<wicri:noRegion>Victoria 3052</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Iannello, Pina" sort="Iannello, Pina" uniqKey="Iannello P" first="Pina" last="Iannello">Pina Iannello</name>
</author>
<author><name sortKey="Jachno, Kim" sort="Jachno, Kim" uniqKey="Jachno K" first="Kim" last="Jachno">Kim Jachno</name>
</author>
<author><name sortKey="Komadina, Naomi" sort="Komadina, Naomi" uniqKey="Komadina N" first="Naomi" last="Komadina">Naomi Komadina</name>
</author>
<author><name sortKey="Hampson, Alan W" sort="Hampson, Alan W" uniqKey="Hampson A" first="Alan W" last="Hampson">Alan W. Hampson</name>
</author>
<author><name sortKey="Barr, Ian G" sort="Barr, Ian G" uniqKey="Barr I" first="Ian G" last="Barr">Ian G. Barr</name>
</author>
<author><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16641465</idno>
<idno type="pmid">16641465</idno>
<idno type="doi">10.1128/AAC.50.5.1872-1874.2006</idno>
<idno type="pmc">PMC1472236</idno>
<idno type="wicri:Area/Main/Corpus">003E15</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003E15</idno>
<idno type="wicri:Area/Main/Curation">003E15</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003E15</idno>
<idno type="wicri:Area/Main/Exploration">003E15</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.</title>
<author><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name>
<affiliation wicri:level="1"><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Rd., Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Rd., Parkville, Victoria 3052</wicri:regionArea>
<wicri:noRegion>Victoria 3052</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Iannello, Pina" sort="Iannello, Pina" uniqKey="Iannello P" first="Pina" last="Iannello">Pina Iannello</name>
</author>
<author><name sortKey="Jachno, Kim" sort="Jachno, Kim" uniqKey="Jachno K" first="Kim" last="Jachno">Kim Jachno</name>
</author>
<author><name sortKey="Komadina, Naomi" sort="Komadina, Naomi" uniqKey="Komadina N" first="Naomi" last="Komadina">Naomi Komadina</name>
</author>
<author><name sortKey="Hampson, Alan W" sort="Hampson, Alan W" uniqKey="Hampson A" first="Alan W" last="Hampson">Alan W. Hampson</name>
</author>
<author><name sortKey="Barr, Ian G" sort="Barr, Ian G" uniqKey="Barr I" first="Ian G" last="Barr">Ian G. Barr</name>
</author>
<author><name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (pharmacology)</term>
<term>Amino Acid Substitution (MeSH)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Baculoviridae (genetics)</term>
<term>Base Sequence (MeSH)</term>
<term>Cyclopentanes (pharmacology)</term>
<term>Drug Resistance, Viral (genetics)</term>
<term>Enzyme Inhibitors (pharmacology)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Female (MeSH)</term>
<term>Guanidines (pharmacology)</term>
<term>Humans (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Influenza B virus (drug effects)</term>
<term>Influenza B virus (isolation & purification)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (virology)</term>
<term>Inhibitory Concentration 50 (MeSH)</term>
<term>Microbial Sensitivity Tests (MeSH)</term>
<term>Molecular Sequence Data (MeSH)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Neuraminidase (genetics)</term>
<term>Oseltamivir (MeSH)</term>
<term>Pyrans (pharmacology)</term>
<term>Recombinant Proteins (antagonists & inhibitors)</term>
<term>Sialic Acids (pharmacology)</term>
<term>Zanamivir (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acides sialiques (pharmacologie)</term>
<term>Acétamides (pharmacologie)</term>
<term>Antienzymes (pharmacologie)</term>
<term>Antienzymes (usage thérapeutique)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Baculoviridae (génétique)</term>
<term>Concentration inhibitrice 50 (MeSH)</term>
<term>Cyclopentanes (pharmacologie)</term>
<term>Données de séquences moléculaires (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Guanidines (pharmacologie)</term>
<term>Humains (MeSH)</term>
<term>Nourrisson (MeSH)</term>
<term>Oséltamivir (MeSH)</term>
<term>Protéines recombinantes (antagonistes et inhibiteurs)</term>
<term>Pyrannes (pharmacologie)</term>
<term>Résistance virale aux médicaments (génétique)</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
<term>Sialidase (génétique)</term>
<term>Substitution d'acide aminé (MeSH)</term>
<term>Séquence nucléotidique (MeSH)</term>
<term>Tests de sensibilité microbienne (MeSH)</term>
<term>Virus influenza B (effets des médicaments et des substances chimiques)</term>
<term>Virus influenza B (isolement et purification)</term>
<term>Zanamivir (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
<term>Recombinant Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Cyclopentanes</term>
<term>Enzyme Inhibitors</term>
<term>Guanidines</term>
<term>Pyrans</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protéines recombinantes</term>
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Baculoviridae</term>
<term>Drug Resistance, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Baculoviridae</term>
<term>Résistance virale aux médicaments</term>
<term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acides sialiques</term>
<term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
<term>Cyclopentanes</term>
<term>Guanidines</term>
<term>Pyrannes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Substitution</term>
<term>Base Sequence</term>
<term>Female</term>
<term>Humans</term>
<term>Infant</term>
<term>Inhibitory Concentration 50</term>
<term>Microbial Sensitivity Tests</term>
<term>Molecular Sequence Data</term>
<term>Oseltamivir</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Concentration inhibitrice 50</term>
<term>Données de séquences moléculaires</term>
<term>Femelle</term>
<term>Humains</term>
<term>Nourrisson</term>
<term>Oséltamivir</term>
<term>Substitution d'acide aminé</term>
<term>Séquence nucléotidique</term>
<term>Tests de sensibilité microbienne</term>
<term>Zanamivir</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An influenza B virus from an infant with no history of treatment or contact with neuraminidase inhibitors demonstrated a significant reduction in sensitivity to these drugs. Here, we describe the analysis of a mixed viral population that contained a novel D197E amino acid substitution that was responsible for this reduction.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16641465</PMID>
<DateCompleted><Year>2006</Year>
<Month>06</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4804</ISSN>
<JournalIssue CitedMedium="Print"><Volume>50</Volume>
<Issue>5</Issue>
<PubDate><Year>2006</Year>
<Month>May</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient.</ArticleTitle>
<Pagination><MedlinePgn>1872-4</MedlinePgn>
</Pagination>
<Abstract><AbstractText>An influenza B virus from an infant with no history of treatment or contact with neuraminidase inhibitors demonstrated a significant reduction in sensitivity to these drugs. Here, we describe the analysis of a mixed viral population that contained a novel D197E amino acid substitution that was responsible for this reduction.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurt</LastName>
<ForeName>Aeron C</ForeName>
<Initials>AC</Initials>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Rd., Parkville, Victoria 3052, Australia. Aeron.Hurt@influenzacentre.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Iannello</LastName>
<ForeName>Pina</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y"><LastName>Jachno</LastName>
<ForeName>Kim</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Komadina</LastName>
<ForeName>Naomi</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hampson</LastName>
<ForeName>Alan W</ForeName>
<Initials>AW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Barr</LastName>
<ForeName>Ian G</ForeName>
<Initials>IG</Initials>
</Author>
<Author ValidYN="Y"><LastName>McKimm-Breschkin</LastName>
<ForeName>Jennifer L</ForeName>
<Initials>JL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName>
<AccessionNumberList><AccessionNumber>DQ174087</AccessionNumber>
<AccessionNumber>DQ174088</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000081">Acetamides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003517">Cyclopentanes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006146">Guanidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011714">Pyrans</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012794">Sialic Acids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.2.1.18</RegistryNumber>
<NameOfSubstance UI="D009439">Neuraminidase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>L6O3XI777I</RegistryNumber>
<NameOfSubstance UI="D053243">Zanamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>QW7Y7ZR15U</RegistryNumber>
<NameOfSubstance UI="C414210">peramivir</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000081" MajorTopicYN="N">Acetamides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016367" MajorTopicYN="N">Baculoviridae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003517" MajorTopicYN="N">Cyclopentanes</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006146" MajorTopicYN="N">Guanidines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020128" MajorTopicYN="N">Inhibitory Concentration 50</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008826" MajorTopicYN="N">Microbial Sensitivity Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009439" MajorTopicYN="N">Neuraminidase</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011714" MajorTopicYN="N">Pyrans</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012794" MajorTopicYN="N">Sialic Acids</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053243" MajorTopicYN="N">Zanamivir</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2006</Year>
<Month>6</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">16641465</ArticleId>
<ArticleId IdType="pii">50/5/1872</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.50.5.1872-1874.2006</ArticleId>
<ArticleId IdType="pmc">PMC1472236</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2001 Feb;20(2):127-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11224828</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1895-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11779389</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2002 May;54(2):79-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12062393</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2002 Aug;55(2):307-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12103431</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2004 Apr;62(1):37-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15026200</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):199-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2001 Feb 15;183(4):523-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11170976</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Aug 28-Sep 3;364(9436):759-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15337401</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1992 Jan;11(1):49-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1740114</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proteins. 1992 Nov;14(3):327-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1438172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Protein Sci. 1994 Oct;3(10):1687-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7849585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1998 Nov;178(5):1257-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9780244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2000 Jul;47(1):1-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10930642</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):205-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163511</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><noCountry><name sortKey="Barr, Ian G" sort="Barr, Ian G" uniqKey="Barr I" first="Ian G" last="Barr">Ian G. Barr</name>
<name sortKey="Hampson, Alan W" sort="Hampson, Alan W" uniqKey="Hampson A" first="Alan W" last="Hampson">Alan W. Hampson</name>
<name sortKey="Iannello, Pina" sort="Iannello, Pina" uniqKey="Iannello P" first="Pina" last="Iannello">Pina Iannello</name>
<name sortKey="Jachno, Kim" sort="Jachno, Kim" uniqKey="Jachno K" first="Kim" last="Jachno">Kim Jachno</name>
<name sortKey="Komadina, Naomi" sort="Komadina, Naomi" uniqKey="Komadina N" first="Naomi" last="Komadina">Naomi Komadina</name>
<name sortKey="Mckimm Breschkin, Jennifer L" sort="Mckimm Breschkin, Jennifer L" uniqKey="Mckimm Breschkin J" first="Jennifer L" last="Mckimm-Breschkin">Jennifer L. Mckimm-Breschkin</name>
</noCountry>
<country name="Australie"><noRegion><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003D64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003D64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Bois |area= PoplarV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:16641465 |texte= Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16641465" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a PoplarV1
This area was generated with Dilib version V0.6.37. |